Bellicum to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
Bellicum Pharmaceuticals (NASDAQ:BLCM) will report its fourth quarter and full year 2020 financial results on March 30, 2021, after U.S. market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bellicum Pharmaceuticals (NASDAQ:BLCM) will report its fourth quarter and full year 2020 financial results on March 30, 2021, after U.S. market close. The management team will host a webcast and conference call at 5 p.m. ET to discuss these results. Bellicum focuses on developing controllable cell therapies for cancer treatment, specifically its GoCAR-T® candidates, BPX-601 and BPX-603. More details will be accessible on their website after the event.
Positive
- Upcoming financial results may show progress in clinical development and investor interest.
- Management will provide a corporate update during the conference call.
Negative
- None.
Details
News Market Reaction – BLCM
The recorded move for BLCM in the trading session of this news was -8.48%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Management to host webcast and conference call on Tuesday, March 30, 2021 at 5 p.m. ET / 2 p.m. PT
HOUSTON, March 23, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will report financial results for the fourth quarter and full year 2020 after the close of U.S. markets on Tuesday, March 30, 2021. Management will host a webcast and conference call at 5 p.m. ET / 2 p.m. PT that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 877-407-3103 (U.S. domestic) and 201-493-6791 (international) at least 10 minutes prior to the start of the call. The event will be webcast live and can also be accessed in the Events & Presentations section of bellicum.com. An archived version of the webcast will be available for replay in the Investors & Media section of the Bellicum website following the call.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com.
Source: Bellicum Pharmaceuticals
Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
858-356-5932
Robert.uhl@westwicke.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.